Wegovy or Zepbound? A Clear-Eyed Comparison (2026)
If you’ve been going back and forth between Wegovy and Zepbound, you’re in good company — they get mixed up constantly, and the honest answer is that the “right” one depends on your goals, your insurance, and how your body responds. Let’s walk through the real differences together so the decision feels less like a coin flip.
Written by the Barrett's Research team · Seed content — please verify before relying on it.
The quick answer
In short: Wegovy (Semaglutide) helps people lose around 15–17% of their body weight at roughly $1,349/mo, while Zepbound (Tirzepatide) averages about 20–22% at roughly $1,060/mo. Neither is a clear winner for everyone — what tips the scale is your goals, what your insurance covers, and how your body takes to it.
The two, side by side
| Feature | Wegovy | Zepbound |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Drug class | GLP-1 receptor agonist | Dual GLP-1/GIP receptor agonist |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA approved for | Chronic weight management + CV risk | Chronic weight management |
| Approval year | 2021 | 2023 |
| Doses | 0.25mg to 2.4mg weekly | 2.5mg to 15mg weekly |
| Administration | Weekly injection (pen) · oral pill option | Weekly injection (pen / vial) |
| Avg. weight loss | 15–17% | 20–22% |
| A1C reduction | 1.5–1.8% | 1.9–2.4% |
| Monthly cost (list) | $1,349 | $1,060 |
| Oral available | Yes | No |
Prices shown are typical self-pay list costs without insurance. Seed data — please verify before relying on it.
Wegovy
15–17%
avg. body-weight loss
The same medicine as Ozempic, dosed higher and approved specifically to help you lose weight. There's now an oral pill version too, if needles aren't your thing.
$1,349/mo list price
Zepbound
20–22%
avg. body-weight loss
The same tirzepatide as Mounjaro, approved specifically for weight management. In trials it delivers the highest average weight loss of any GLP-1 you can get today.
$1,060/mo list price
Wegovy might be your match if…
- Your plan covers it but not Zepbound — let coverage lead.
- A longer track record puts you at ease (it’s been around since 2021).
- You’re already doing well on Semaglutide and would rather not switch.
Zepbound might be your match if…
- The strongest possible weight loss is your top priority (20–22%).
- You’re drawn to its dual glp-1/gip receptor agonist approach.
- Your plan covers Zepbound (or its weight-loss version).
Let’s find the right program for you
We’ll show you the vetted telehealth programs that can prescribe these medications, so the next step is easy.
The takeaway
Neither Wegovy nor Zepbound is simply “better” — they’re both well-studied GLP-1 medications, and most people do well on the one their plan covers and their prescriber recommends. Lead with whichever your insurance helps pay for, factor in the weight-loss results you’re hoping for, and let your doctor fine-tune the dose from there. You don’t have to get this perfect on the first try; treatment is meant to be adjusted as you go.
Related Resources
Our 2026 Program Rankings
See how all six programs stack up, side by side.
Compounded or Brand-Name?
What the end of the semaglutide shortage means for you.
Medicare GLP-1 Coverage
From July 2026, Medicare covers GLP-1 at $50 a month.
Handling Side Effects
Friendly tips for getting through the common GLP-1 side effects.
Find Your Match
A two-minute quiz to point you toward the right fit.
The Most Affordable Programs
Compare the options by what you'd actually pay.
Not sure which program is the right fit?
Answer six quick questions and we'll point you to the programs that suit your budget, your insurance, and how you want to be cared for.